These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7666077)

  • 1. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
    Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
    J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
    Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
    J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
    J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
    J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
    J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
    Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
    Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
    Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
    J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
    Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
    J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
    Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Safarinejad MR
    Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
    Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
    J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
    Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
    J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
    Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O
    Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
    Bitton RJ; Figg WD; Venzon DJ; Dalakas MC; Bowden C; Headlee D; Reed E; Myers CE; Cooper MR
    J Clin Oncol; 1995 Sep; 13(9):2223-9. PubMed ID: 7666080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
    Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
    Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
    Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F
    J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.